Development of next-generation gapmer antisense oligonucleotides targeting periostin for intraocular proliferative disease
| Project/Area Number |
16K15734
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
園田 康平 九州大学, 医学研究院, 教授 (10294943)
池田 康博 九州大学, 医学研究院, 准教授 (20380389)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ペリオスチン / 糖尿病網膜症 / 加齢黄斑変性 / アンチセンス / マトリセルラー蛋白 |
|---|
| Outline of Final Research Achievements |
Recently, a number of studies have demonstrated the effects of anti-vascular endothelial growth factor (VEGF) treatment on intraocular proliferation in eyes with age-related macular degeneration and diabetic retinopathy. However, despite the frequent intravitreal injection of the anti-VEGF drugs, its effect is often limited. As a disease responsible molecule for intraocular ploriferative diseases, we have successfully identified periostin, a matricellular protein. On the other hand, a next-generation gapmer antisense oligonucleotides that is stable with high safety has been recently developed. In this study, the next generation antisense oligonucleotides targeting periostin was synthesized. Periostin-targeting gapmer antisense oligonucleotides significantly inhibited fibrovascular proliferation both in vitro and in vivo models of intraocular proliferation .
|
Report
(3 results)
Research Products
(5 results)
